Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

被引：116

作者：

Hartmaier, Ryan J. ^{[1
]}

Markovets, Aleksandra A. ^{[1
]}

Ahn, Myung Ju ^{[2
]}

Sequist, Lecia, V ^{[3
]}

Han, Ji-Youn ^{[4
]}

Cho, Byoung Chul ^{[5
]}

Yu, Helena A. ^{[6
]}

Kim, Sang-We ^{[7
]}

Yang, James Chih-Hsin ^{[8
]}

Lee, Jong-Seok ^{[9
]}

Su, Wu-Chou ^{[10
]}

Kowalski, Dariusz M. ^{[11
]}

Orlov, Sergey ^{[12
]}

Ren, Song ^{[13
]}

Frewer, Paul ^{[14
]}

Ou, Xiaoling ^{[14
]}

Cross, Darren A. E. ^{[15
]}

Kurian, Nisha ^{[16
]}

Cantarini, Mireille ^{[15
]}

Jaenne, Pasi A. ^{[17
]}

机构：

[1] AstraZeneca, Oncol R&D, Res & Early Dev, Translat Med, Boston, MA USA

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[4] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[5] Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Coll Med, Seoul, South Korea

[6] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA

[7] Univ Uslan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea

[8] Natl Taiwan Univ, Dept Med Oncol, Canc Ctr, Taipei, Taiwan

[9] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seoul, South Korea

[10] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Oncol, Warsaw, Poland

[12] BioEq LLC, St Petersburg, Russia

[13] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Gaithersburg, MD USA

[14] AstraZeneca, Oncol R&D, Oncol Biometr, Cambridge, England

[15] AstraZeneca, Oncol R&D, Oncol Late Dev, Cambridge, England

[16] AstraZeneca, Oncol R&D, Precis Med & Biosamples, Boston, MA USA

[17] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

CANCER DISCOVERY | 2023年 / 13卷 / 01期

关键词：

TYROSINE KINASE INHIBITORS; PHASE-II PLATFORM; PATIENT; NSCLC; CRIZOTINIB; VOLITINIB; THERAPY; DISEASE; AZD9291; POTENT;

D O I：

10.1158/2159-8290.CD-22-0586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the fi nal phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n= 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osimertinib 80 mg q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) and progression on prior EGFR-TKI. An accept-able safety profi le was observed. In Parts B and D, respectively, objective response rates were 33% to 67% and 62%, and median progression-free survival (PFS) was 5.5 to 11.1 months and 9.0 months. Increased antitumor activity may occur with MET copy number >= 10. EGFRm circulating tumor DNA clearance on treatment predicted longer PFS in patients with detectable baseline ctDNA, while acquired resistance mechanisms to osimertinib + savolitinib were mediated by MET, EGFR, or KRAS alterations. SIGNIFICANCE: The savolitinib + osimertinib combination represents a promising therapy in patients with MET-amplifi ed/overexpressed, EGFRm advanced NSCLC with disease progression on a prior EGFR-TKI. Acquired resistance mechanisms to this combination include those via MET, EGFR, and KRAS. On-treatment ctDNA dynamics can predict clinical outcomes and may provide an opportunity to inform earlier decision-making.

引用

页码：98 / 113

页数：16

共 47 条

[31] Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC [J].

Recondo, Gonzalo ;

Bahcall, Magda ;

Spurr, Liam F. ;

Che, Jianwei ;

Ricciuti, Biagio ;

Leonardi, Giulia C. ;

Lo, Ying-Chun ;

Li, Yvonne Y. ;

Lamberti, Giuseppe ;

Nguyen, Tom ;

Milan, Marina S. D. ;

Venkatraman, Deepti ;

Umeton, Renato ;

Paweletz, Cloud P. ;

Albayrak, Adem ;

Cherniack, Andrew D. ;

Price, Kristin S. ;

Fairclough, Stephen R. ;

Nishino, Mizuki ;

Sholl, Lynette M. ;

Oxnard, Geoffrey R. ;

Janne, Pasi A. ;

Awad, Mark M. .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2615-2625

[32] CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Reungwetwattana, Thanyanan ;

Nakagawa, Kazuhiko ;

Cho, Byoung Chul ;

Cobo, Manuel ;

Cho, Eun Kyung ;

Bertolini, Alessandro ;

Bohnet, Sabine ;

Zhou, Caicun ;

Lee, Ki Hyeong ;

Nogami, Naoyuki ;

Okamoto, Isamu ;

Leighl, Natasha ;

Hodge, Rachel ;

McKeown, Astrid ;

Brown, Andrew P. ;

Rukazenkov, Yuri ;

Ramalingam, Suresh S. ;

Vansteenkiste, Johan .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) :3290-+

[33] Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study [J].

Sequist, Lecia, V ;

Han, Ji-Youn ;

Ahn, Myung-Ju ;

Cho, Byoung Chul ;

Yu, Helena ;

Kim, Sang-We ;

Yang, James Chih-Hsin ;

Lee, Jong Seok ;

Su, Wu-Chou ;

Kowalski, Dariusz ;

Orlov, Sergey ;

Cantarini, Mireille ;

Verheijen, Remy B. ;

Mellemgaard, Anders ;

Ottesen, Lone ;

Frewer, Paul ;

Ou, Xiaoling ;

Oxnard, Geoffrey .

LANCET ONCOLOGY, 2020, 21 (03) :373-386

[34] Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].

Sequist, Lecia V. ;

Waltman, Belinda A. ;

Dias-Santagata, Dora ;

Digumarthy, Subba ;

Turke, Alexa B. ;

Fidias, Panos ;

Bergethon, Kristin ;

Shaw, Alice T. ;

Gettinger, Scott ;

Cosper, Arjola K. ;

Akhavanfard, Sara ;

Heist, Rebecca S. ;

Temel, Jennifer ;

Christensen, James G. ;

Wain, John C. ;

Lynch, Thomas J. ;

Vernovsky, Kathy ;

Mark, Eugene J. ;

Lanuti, Michael ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)

[35] Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. [J].

Shepherd, Frances A. ;

Papadimitrakopoulou, Vassiliki ;

Mok, Tony ;

Wu, Yi-Long ;

Han, Ji-Youn ;

Ahn, Myung-Ju ;

Ramalingam, Suresh S. ;

John, Tom ;

Sebastian, Martin ;

Theelen, Willemijn ;

Laus, Gianluca ;

Collins, Barbara ;

Markovets, Aleksandra ;

Thress, Kenneth S. ;

Oxnard, Geoffrey R. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[36] INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance [J].

Smit, Egbert F. ;

Dooms, Christophe ;

Raskin, Jo ;

Nadal, Ernest ;

Tho, Lye M. ;

Le, Xiuning ;

Mazieres, Julien ;

Hin, How S. ;

Morise, Masahire ;

Zhu, Viola W. ;

Tan, Daniel ;

Holmberg, Kristina H. ;

Ellers-Lenz, Barbara ;

Adrian, Svenja ;

Brutlach, Sabine ;

Schumacher, Karl M. ;

Karachaliou, Niki ;

Wu, Yi-Long .

FUTURE ONCOLOGY, 2022, 18 (09) :1039-1054

[37] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

[38] Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis [J].

Wang, Chunsheng ;

Zhao, Kewei ;

Hu, Shanliang ;

Li, Minghuan ;

Song, Yipeng .

FRONTIERS IN ONCOLOGY, 2021, 11

[39] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Tsuboi, Masahiro ;

He, Jie ;

John, Thomas ;

Grohe, Christian ;

Majem, Margarita ;

Goldman, Jonathan W. ;

Laktionov, Konstantin ;

Kim, Sang-We ;

Kato, Terufumi ;

Vu, Huu-Vinh ;

Lu, Shun ;

Lee, Kye-Young ;

Akewanlop, Charuwan ;

Yu, Chong-Jen ;

de Marinis, Filippo ;

Bonanno, Laura ;

Domine, Manuel ;

Shepherd, Frances A. ;

Zeng, Lingmin ;

Hodge, Rachel ;

Atasoy, Ajlan ;

Rukazenkov, Yuri ;

Herbst, Roy S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18) :1711-1723

[40] Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial [J].

Wu, Yi-Long ;

Cheng, Ying ;

Zhou, Jianying ;

Lu, Shun ;

Zhang, Yiping ;

Zhao, Jun ;

Kim, Dong-Wan ;

Soo, Ross Andrew ;

Kim, Sang-We ;

Pan, Hongming ;

Chen, Yuh-Min ;

Chian, Chih-Feng ;

Liu, Xiaoqing ;

Tan, Daniel Shao Weng ;

Bruns, Rolf ;

Straub, Josef ;

Johne, Andreas ;

Scheele, Jurgen ;

Park, Keunchil ;

Yang, James Chih-Hsin .

LANCET RESPIRATORY MEDICINE, 2020, 8 (11) :1132-1143

← 1 2 3 4 5 →